ATYR Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for aTyr Pharma Inc (ATYR), indicating a "Strong Buy" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights for potential investors.
[ARS] aTYR PHARMA INC SEC Filing
This article announces an ARS SEC filing by aTYR PHARMA INC (ATYR) on March 26, 2026, detailing that the filing impact is low and the sentiment is neutral. It provides a link to view the PDF document on SEC EDGAR and lists recent news and SEC filings for the company. The article also includes key stock data for ATYR.
Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR)
Vanguard has filed an amended Schedule 13G for aTyr Pharma (ATYR), reporting 0 shares beneficially owned and 0% of common stock. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries will now report beneficial ownership separately, as per SEC guidance. This is an administrative reclassification, not an economic disposition, and subsequent filings from Vanguard affiliates are expected to show their individual holdings.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts
aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus "Hold" recommendation from seven analysts, with an average 12-month price target of $25.67. The clinical-stage biotech, focused on rare disease therapies, recently reported better-than-expected EPS and analysts predict -0.91 EPS for the current fiscal year. Institutional investors hold a significant 61.72% of the company's stock, which recently traded down 4.6% at $0.79.
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen
Wall Street Zen has upgraded aTyr Pharma (NASDAQ:ATYR) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with an average price target of $25.67. The company's stock currently trades around $0.85, and it recently reported a quarterly EPS beat of ($0.14) against an estimated ($0.18). Institutional investors, including several hedge funds, now own approximately 61.72% of the company's shares.
aTyr Pharma Inc Stock (ISIN: US53227K1025) Faces Uncertainty Amid Delisting Risk and Pipeline Focus
aTyr Pharma Inc (NASDAQ: LIFE) is facing delisting risks while investors focus on its lead candidate, efzofitimod, which is in Phase III trials for pulmonary sarcoidosis. The company, which specializes in tRNA synthetase biology in immunology, maintains a micro-cap valuation of $131 million and is navigating financial hurdles, including a burn rate that projects cash into 2027. Despite financial pressures, aTyr's pipeline and strategic partnerships, like the one with Kyorin Pharmaceutical, offer potential for future growth if efzofitimod achieves clinical success.
aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M
aTyr Pharma is seeking shareholder approval to double its authorized common stock from 170 million to 340 million shares at its 2026 Annual Meeting. This increase is intended to provide greater flexibility for future financial activities, including capital raising, strategic partnerships, and employee equity incentives. Shareholders will also vote on the election of directors, ratification of auditors, and an advisory vote on executive compensation.
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
aTyr Pharma presented insights from its Phase 3 EFZO-FIT study for efzofitimod, a therapy for pulmonary sarcoidosis, noting that while the primary steroid-reduction endpoint was narrowly missed, secondary endpoints showed significant quality-of-life improvements. The company has a Type C meeting with the FDA in mid-April to discuss the trial results and potential future development, preparing for the possibility of another study focusing on quality-of-life and pulmonary function. aTyr also highlighted its broader platform, pipeline updates for ATYR0101 and EFZO-CONNECT, and a strong financial position with $80 million in cash.
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (ATYR) with a $20.00 price target, based on a report from March 6. This is despite aTyr Pharma having a consensus analyst rating of Hold with a price target of $7.33. The company recently reported a quarterly GAAP net loss of $13.96 million, an improvement from the previous year.
Investigation announced for Long-Term Investors in shares
An investigation has been announced on behalf of long-term investors in aTyr Pharma, Inc. (NASDAQ: ATYR) concerning potential breaches of fiduciary duties by its directors. This follows a lawsuit alleging securities law violations and claims that the company concealed material adverse facts regarding the efficacy of its drug, Efzofitimod, leading to a significant stock decline. Investors are encouraged to contact the Shareholders Foundation for options.
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook
Jefferies has reiterated a Buy rating and a $3.00 price target for aTyr Pharma (NASDAQ:ATYR) despite the company's efzofitimod drug candidate missing a primary endpoint in its EFZO-FIT trial. The firm believes that a shift in medical practice away from chronic oral corticosteroid use could lead the FDA to require another adequately controlled trial focusing on symptom and functional measures. aTyr Pharma recently announced that the FDA has agreed to a Type C meeting in mid-April 2026 to review data from the Phase 3 EFZO-FIT study.
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
Atyr Pharma Inc. (ATYR) is at risk of being delisted from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. The company received a deficiency notice on December 4, 2025, and failure to regain compliance, possibly through a reverse stock split, could lead to delisting. This would likely reduce liquidity, increase volatility, and make it harder for the company to access capital and maintain investor confidence.
Jefferies Maintains Buy on ATYR aTyr Pharma, Inc. March 2026
Jefferies reiterated a "Buy" rating on aTyr Pharma, Inc. (ATYR) on March 6, 2026, despite noting a low probability of immediate approval for its drug EFZO‑FIT due to regulatory risks. The firm believes in the drug's long-term value, leading to the maintained positive outlook. At the time of the note, ATYR experienced a modest intraday price drop of -0.52%, with a market capitalization of $80,740,986.
Atyr Pharma: Fourth Quarter Earnings Overview
Atyr Pharma Inc. reported a net loss of $14 million for the fourth quarter, or $0.14 per share, surpassing analyst expectations of a $0.18 per share loss. For the full year, the company's net loss amounted to $74.1 million ($0.80 per share), with annual revenue remaining stable at approximately $190,000. Significantly, the stock price closed at $0.90 per share, down from $3.15 a year prior.
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
aTyr Pharma (NASDAQ:ATYR) reported quarterly earnings of ($0.14) per share, surpassing analyst expectations by $0.04. Despite beating estimates, the company's shares fell by 6.4%, trading at $0.90, with a market capitalization of approximately $88.4 million. Analyst consensus rates the stock as "Hold" with a wide target price divergence from its current trading value.
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma released its fourth quarter and full year 2025 financial results and provided a corporate update, including plans to meet with the FDA in mid-April 2026 to discuss the path forward for efzofitimod in pulmonary sarcoidosis. The company's Phase 3 EFZO-FIT™ study did not meet its primary endpoint but showed clinical benefits on secondary efficacy parameters for the 5.0 mg/kg dose. Enrollment for the Phase 2 EFZO-CONNECT™ study in SSc-ILD is expected to be completed in the first half of 2026, and aTyr Pharma ended 2025 with $80.9 million in cash and investments.
aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday
aTyr Pharma (NASDAQ:ATYR) is expected to announce its Q4 2025 earnings before the market opens on Thursday, March 12th, with analysts forecasting a loss of ($0.18) per share and revenue of $0.02 million. The company's shares opened at $0.96, and institutional investors own approximately 61.72% of the stock. Analysts currently hold a consensus "Hold" rating for ATYR, with a target price of $25.67.
Atyr Pharma: Q4 Earnings Snapshot
Atyr Pharma Inc. reported a Q4 loss of $14 million, or 14 cents per share, surpassing Wall Street's expectation of an 18-cent loss. For the full year, the company's loss expanded to $74.1 million, or 80 cents per share, with revenue remaining nearly flat at $190,000. Following the earnings report, shares of Atyr Pharma Inc. closed at 90 cents on Thursday, a significant decrease from $3.15 a year ago.
After key study miss, FDA to weigh aTyr lung disease drug in April
aTyr Pharma announced its fourth quarter and full-year 2025 results, ending the year with $80.9 million in cash. The Phase 3 EFZO-FIT study for its lung disease drug, efzofitimod, did not meet its primary endpoint, but 5.0 mg/kg efzofitimod showed clinical benefit on several secondary measures. A Type C meeting with the FDA is scheduled for mid-April 2026 to discuss the path forward for efzofitimod in pulmonary sarcoidosis.
ATYR Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts
Analysts have issued a "Hold" consensus recommendation for aTyr Pharma (NASDAQ:ATYR), with an average 12-month price target of $25.67. One analyst issued a sell rating, five a hold, and one a buy, while Weiss Ratings independently reiterated a "sell (d-)" rating. Institutional investors collectively own 61.72% of the company, with notable stake increases from firms like Vanguard Group Inc. and UBS Group AG in recent quarters.
aTyr Pharma (ATYR) Stock Analysis: Exploring a Potential 327% Upside in the Biotech Sector
aTyr Pharma (ATYR) is presented as a high-risk, high-reward investment opportunity in the biotechnology sector, focusing on innovative therapies for fibrosis and inflammation. Despite negative financial metrics typical of clinical-stage biotechs, the company exhibits a potential upside of 327.17% driven by analyst target prices and the progress of its lead therapeutic, efzofitimod, in clinical trials. Investors are cautioned about the inherent volatility and dependence on successful trial outcomes for this cutting-edge biotech development.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees for an aggregate of 12,200 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4) and the aTyr Pharma, Inc. 2022 Inducement Plan, have an exercise price of $0.98 per share and vest over four years, contingent on continued employment. The move aims to attract and retain new talent for the clinical-stage biotechnology company.
Biotech aTyr gives new employees 12,200 stock options at $0.98
aTyr Pharma announced it granted 12,200 nonstatutory stock options to two new employees on February 17, 2026, with an exercise price of $0.98 per share, matching the closing price on that date. These options vest over four years and were issued under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) as an incentive for their employment. The company’s stock, ATYR, declined 2.88% on the day this news was published, reflecting a moderate negative market reaction according to StockTitan Argus.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees for an aggregate of 12,200 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are an inducement for their employment. The options vest over four years, with a 25% initial vest and monthly installments thereafter.
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. announced that its Compensation Committee granted nonstatutory stock options to two new employees. These options allow them to purchase a total of 12,200 shares of common stock at $0.98 per share, effective February 17, 2026. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the aTyr Pharma, Inc. 2022 Inducement Plan, vesting over four years.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees to purchase an aggregate of 12,200 shares of common stock. These grants, with an exercise price of $0.98 per share, were made as an inducement for employment under Nasdaq Listing Rule 5635(c)(4) and vest over four years, subject to continued employment.
Final visit completed in Phase 3 EFZO-FIT clinical trial of efzofitimod
The Phase 3 EFZO-FIT clinical trial for Atyr Pharma’s experimental treatment, efzofitimod, for pulmonary sarcoidosis has completed its final patient visit. Top-line results are anticipated in the third quarter of this year. Efzofitimod aims to reduce inflammation and scarring by targeting activated myeloid cells, potentially offering a steroid-sparing treatment option to improve the quality of life for patients.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: ATYR) announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The company, a clinical-stage biotechnology firm, will discuss its proprietary tRNA synthetase platform and its lead therapeutic candidate, efzofitimod, which is in development for interstitial lung disease. Management will also be available for one-on-one investor meetings at the conference.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, a clinical stage biotechnology company, announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The presentation will cover the company's progress in developing first-in-class medicines from its proprietary tRNA synthetase platform, including its lead therapeutic candidate, efzofitimod, for interstitial lung disease. Management will also be available for one-on-one meetings with investors.
Biotech aTyr Pharma CEO to speak at Miami global healthcare conference
aTyr Pharma (Nasdaq: ATYR) announced that its President and CEO, Sanjay S. Shukla, will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. The presentation will cover corporate updates, and management will also be available for one-on-one meetings with registered investors. A live webcast and replay will be accessible on the company's website.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, Inc. announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The company, a clinical-stage biotechnology firm, specializes in developing therapies for fibrosis and inflammation using its proprietary tRNA synthetase platform. Management will also be available for one-on-one meetings with investors, and a webcast will be available on the company's website.
aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings
Insiders at aTyr Pharma, Inc. have significantly increased their stock holdings over the last year, with an Independent Director making a large US$912k purchase near the current share price. This indicates increased optimism about the company's future prospects, despite relatively low overall insider ownership (2.5%). While there haven't been recent insider transactions, the past year's buying activity is seen as an encouraging sign.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, Inc. announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL. The presentation is scheduled for Wednesday, March 11, 2026, at 8:00 AM EDT. The company will also be available for one-on-one meetings with investors, and a webcast and replay of the presentation will be available on their website.
The Truth About aTyr Pharma Inc (LIFE): Tiny Stock, Huge Bets – But Is It Worth the Hype?
This article provides an in-depth look at aTyr Pharma Inc (LIFE), a clinical-stage biotech company, analyzing its stock performance, scientific focus, and market hype. It highlights the high-risk, high-reward nature of investing in LIFE due to its experimental pipeline targeting lung and immune disorders. The author advises caution, noting the stock's extreme volatility and dependence on clinical trial success for long-term investors.
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth by 2034, driven by increasing prevalence and the launch of new pipeline products. Key players like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing therapies, with Avidity Biosciences showing promising clinical trial results for delpacibart braxlosiran, and Epicrispr Biotechnologies receiving IND clearance for its epigenetic-based treatment, EPI-321. The report highlights that the US accounts for a substantial portion of FSHD cases, and there's a high demand for effective treatments as no approved therapies currently exist.
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected
This week in biotech, aTyr Pharma scheduled an FDA meeting for its Efzofitimod program, while Aquestive Therapeutics received a Complete Response Letter for its Anaphylm application. Sangamo Therapeutics reported positive data from its Fabry disease study, and Novo Nordisk announced strong results for CagriSema in Type 2 Diabetes. Sanofi's Venglustat met primary goals in a Gaucher study but fell short in a Fabry disease trial.
Atyr Pharma CEO Shukla sells $3.6k in stock
Atyr Pharma CEO Shukla Sanjay sold 3,745 shares of common stock for $3,655 to cover tax obligations related to vested restricted stock units. This occurred after acquiring 10,375 shares from RSU vesting, bringing his total direct ownership to 153,553 shares. Separately, aTyr Pharma received FDA acceptance for a Type C meeting in mid-April 2026 to discuss their lead therapeutic candidate, efzofitimod, for pulmonary sarcoidosis.
Atyr Pharma CFO Broadfoot sells $1.5k in stock
Atyr Pharma's CFO, Jill Marie Broadfoot, sold 1,558 shares of common stock for approximately $1,520 after restricted stock units vested. This transaction occurred just before the company announced that the FDA accepted its request for a Type C meeting in mid-April 2026 to discuss efzofitimod for pulmonary sarcoidosis, following positive Phase 3 study results.
aTyr Pharma general counsel sells $1091 in stock
Nancy Denyes, General Counsel at aTyr Pharma INC (NASDAQ:ATYR), sold 1,118 shares of common stock for $1,091 on February 4, 2026. This transaction follows the vesting of restricted stock units and occurs amidst the company's financial challenges and a significant stock price drop over the past year. aTyr Pharma also announced FDA acceptance for a meeting to discuss efzofitimod, a therapeutic candidate for pulmonary sarcoidosis.
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting
aTyr Pharma (NASDAQ:ATYR) announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis. While the primary endpoint was not met, secondary measures showed benefits. The company's stock has seen a 37% return over the past week and nearly 24% year-to-date, despite a significant decline over the past year and negative EBITDA.
aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ)
aTyr Pharma will meet with the FDA in April to discuss the future of its lead drug candidate, efzofitimod, for lung disease. The company's shares fell approximately 8% on Tuesday following the announcement. This meeting is crucial for determining the path forward for the drug.
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
aTyr Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted its meeting request to discuss its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis. The Type C meeting is scheduled for mid-April 2026. The company anticipates providing an update on the meeting's outcome after receiving the official minutes.
aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod
aTyr Pharma (ATYR) is preparing for a crucial FDA Type C meeting in mid-April 2026 to discuss its therapeutic candidate, efzofitimod, for pulmonary sarcoidosis. The company will review the results of its Phase 3 EFZO-FIT study to determine the next steps for approval. Despite financial challenges and significant losses, aTyr Pharma maintains a strong liquidity position, although its valuation metrics suggest potential overvaluation while analyst sentiment remains cautiously optimistic.
FDA sets April meeting on lung sarcoidosis drug efzofitimod trial
aTyr Pharma announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss the efzofitimod program for pulmonary sarcoidosis. The meeting will review results from the Phase 3 EFZO-FIT study, which did not meet its primary endpoint but showed statistically significant benefits in patient-reported outcomes. The company plans to provide an update on the regulatory path following the meeting.
aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has scheduled a Type C meeting with the FDA in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis. Although the study did not meet its primary endpoint for corticosteroid dosage reduction, it showed clinical benefits in several secondary measures like quality of life and fatigue scores, and maintained lung function with a good safety profile. The company expects to provide an update on the development path for efzofitimod after the meeting.
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting
aTyr Pharma announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss efzofitimod, their lead therapeutic candidate for pulmonary sarcoidosis. The company will review Phase 3 EFZO-FIT study results, which showed benefits in secondary measures despite not meeting the primary endpoint of reducing corticosteroid dosage. This meeting is crucial for the company, which is currently burning through cash, to determine the next steps for the drug's development.
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma has announced that the FDA has accepted its request for a Type C meeting to discuss efzofitimod for the treatment of pulmonary sarcoidosis. The meeting is scheduled for mid-April 2026, where the company will review the results of its Phase 3 EFZO-FIT™ study and determine the path forward for the therapeutic candidate. While the study did not meet its primary endpoint, clinical benefits were observed across multiple efficacy parameters.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Brokerages
aTyr Pharma (NASDAQ:ATYR) has received a "Hold" consensus recommendation from seven brokerage firms, with an average 12-month target price of $23.25. The company recently reported weaker-than-expected quarterly earnings and revenue. Despite high institutional ownership, a "sell" rating was reiterated by one firm, and analysts project negative EPS for the current year.
Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR
Federated Hermes Inc. significantly reduced its stake in aTyr Pharma (NASDAQ:ATYR) by selling over 4.1 million shares, cutting its position by 28.1%. This divestment brings Federated Hermes' total holdings in aTyr Pharma to just over 10.5 million shares, representing a 10.76% stake in the company. The reduction comes as aTyr Pharma reported a third-quarter earnings and revenue miss, with the stock currently trading at approximately $0.88.
